Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$103.53
pos +0.00
+0.00%
Today's Range: 102.71 - 104.34 | GILD Avg Daily Volume: 16,766,900
Last Update: 02/27/15 - 4:00 PM EST
Volume: 0
YTD Performance: 9.83%
Open: $0.00
Previous Close: $104.19
52 Week Range: $63.50 - $116.83
Oustanding Shares: 1,489,401,683
Market Cap: 155,180,761,352
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 12 12
Moderate Buy 2 2 2 2
Hold 3 3 3 3
Moderate Sell 1 1 1 0
Strong Sell 0 0 0 0
Mean Rec. 1.65 1.65 1.61 1.47
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 14.18
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
14.18 14.20 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.22% 23.77% 358.20%
GROWTH 12 Mo 3 Yr CAGR
Revenue 15.50 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 15.27B
Revenue 24.89B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $3.16 $2.89 $10.13 $9.28
Number of Analysts 1 1 2 2
High Estimate $3.16 $2.89 $11.12 $10.77
Low Estimate $3.16 $2.89 $9.13 $7.78
Prior Year $1.44 $2.32 $7.91 $10.13
Growth Rate (Year over Year) 119.44% 24.57% 28.00% -8.40%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Update
Feb 25, 2015 | 7:13 AM EST
RBC Healthcare Conference
Why does the market feel like it wants to roll over?

From the Street of Dreams Real Money Pro($)

Deutsche Bank reiterates its Buy recommendation on Gilead (GILD) (price target $125) based on the company's exclusive agreement with AbbVie (ABBV) for its HCV drug.
JNJ provides low-risk, good income and modest appreciation.
Watch this leadership group that's been lagging.
They're in the tech, pharma and biotechnology sectors.
Detached from overseas negatives, the market reacts rationally.
But it doesn't bode well for the euro, Treasuries or metals.
Credit Suisse downgrades Gilead (GILD) this morning.
Bearish
Feb 06, 2015 | 7:00 AM EST
GILD was downgraded from Outperform to Neutral, Credit Suisse said. $115 price target. Company is seeing lower pricing for hepatitis C....

Columnist Conversations

Even before the ECB's asset-buying policy officially started, investors have been rushing into risky assets, d...
I am forever probing companies on what they have planned for growth. New products, new services -- I need "co...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.